News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
All Stories
News
Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond
July 18, 2023
Fierce Biotech
Read Now
Press Release
Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond
July 18, 2023
Fierce Biotech
Read Now
News
Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
July 18, 2023
STAT News
Read Now
Press Release
Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
July 18, 2023
STAT News
Read Now
Press Release
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
July 17, 2023
Read Now
Press Release
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
July 17, 2023
Read Now
News
Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact
July 17, 2023
Endpoints News
Read Now
Press Release
Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact
July 17, 2023
Endpoints News
Read Now